News and Events

Paris, France and Camberley, UK – 3 June 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces it will settle all outstanding debt obligations with Harbert European Growth Capital (“HEGC”) and Vatel Capital SAS (“Vatel”). http://novacyt.com/wp-content/uploads/2020/06/Novacyt-Early-settlement-of-term-loan-03-06-20-ENGLISH.pdf

Paris, France et Camberley, Royaume-Uni – 3 juin 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, annonce avoir réglé toutes ses dettes en cours envers Harbert European Growth Capital (“HEGC”) et Vatel Capital SAS (“Vatel”). http://novacyt.com/wp-content/uploads/2020/06/Novacyt-Règlement-anticipé-du-prêt-à-terme-et-émission-dobligations-convertibles-03-06-20-FRENCH.pdf

Paris, France et Camberley, Royaume-Uni – 2 juin 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, fait le point sur son test d’amplification en chaîne par polymérase (PCR) pour COVID-19, mis au point par Primerdesign, la division de diagnostic moléculaire de la société. http://novacyt.com/wp-content/uploads/2020/06/Novacyt-COVID-19-update-02-06-20-FRENCH.pdf

Paris, France and Camberley, UK – 2 June 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, provides an update on its polymerase chain reaction (PCR) test for COVID-19, developed by Primerdesign, the Company’s molecular diagnostics division. http://novacyt.com/wp-content/uploads/2020/06/Novacyt-COVID-19-update-02-06-20-ENGLISH.pdf

Paris, France and Camberley, UK – 1 June 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by French law and is further summarised in

Paris, France et Camberley, Royaume-Uni – 26 mai 2020 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, annonce avoir été informé, le 25 mai 2020, d’achats d’actions ordinaires de 1/15 € chacune de la Société (les « Actions Ordinaires ») par l’Administrateur suivant : http://novacyt.com/wp-content/uploads/2020/05/Novacyt-Directors-Dealings-FRENCH-26.05.2020.pdf

Paris, France and Camberley, UK – 26 May 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 25 May 2020, the following Director purchased ordinary shares of €1/15 each in the Company (the “Ordinary Shares”): http://novacyt.com/wp-content/uploads/2020/05/Novacyt-Directors-Dealings-ENGLISH-26.05.2020.pdf

Paris, France et Camberley, Royaume-Uni – 14 mai 2020 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, publie ses résultats financiers audités pour l’exercice clos le 31 décembre 2019 et des perspectives pour 2020. http://novacyt.com/wp-content/uploads/2020/05/Novacyt-FY19-financial-results-PR-FRENCH-14.05.2020-FINAL.pdf

Paris, France and Camberley, UK – 14 May 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its audited final results for the year ended 31 December 2019 and provides an outlook for 2020. http://novacyt.com/wp-content/uploads/2020/05/Novacyt-FY19-financial-results-PR-ENGLISH-14.05.2020-FINAL.pdf